Rafael Holdings, Inc. (NYSE:RFL) Short Interest Update

Rafael Holdings, Inc. (NYSE:RFL) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 789,900 shares, a growth of 97.7% from the August 15th total of 399,613 shares. Based on an average daily trading volume, of 124,437 shares, the short-interest ratio is presently 6.3 days. Approximately 2.3% of the shares of the company are short sold.

Hedge Funds Weigh In On Rafael

A hedge fund recently bought a new position in Rafael stock. Kahn Brothers Group Inc. purchased a new position in Rafael Holdings, Inc. (NYSE:RFL) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,493 shares of the company’s stock, valued at approximately $494,000. Kahn Brothers Group Inc. owned 0.29% of Rafael as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.30% of the company’s stock.

Rafael Stock Down 2.3%

RFL traded down $0.05 during trading on Tuesday, reaching $2.13. 25,567 shares of the company were exchanged, compared to its average volume of 126,510. Rafael has a 12-month low of $1.12 and a 12-month high of $3.96. The company’s 50-day moving average is $2.21 and its two-hundred day moving average is $1.83. The company has a market cap of $110.76 million, a price-to-earnings ratio of -3.13 and a beta of 0.40.

Wall Street Analyst Weigh In

RFL has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Rafael in a report on Tuesday, August 25th. Wall Street Zen raised shares of Rafael to a “hold” rating in a report on Saturday, July 25th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.